Accepted at 6:14 p.m. Jun, 29, 2024 by Ahmed7
Author: lawsonspence
Co-authors: Ahmed7
Related Note: 1488767931946 1
Rationale for change

tip from the BnB video

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step2_v12::#SketchyIM::01_Cardiology::05_Blood_Vessel_Disease::01_DVT_SOAP #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::03_Physiology::05_Coagulation_and_kinin_pathways::*Coagulation_Cascade #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::03_Heparin_vs_warfarin::*Heparin #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::01_Bleeding_&_Clotting_Disorders::01_Bleeding_Disorders:_Coagulation_Factor_Disorders_DDx #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::01_Heparin_LMWH_Fondaparinux #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::^Systems::HemeOnc::Hematology #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::01_Heparin,_LMWH,_fondaparinux,_direct_thrombin_inhibitors,_Xa_inhibitors #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::01_Heparin::*Unfractionated_Heparin #AK_Step1_v12::#Pixorize::01_Biochemistry::21_Lab_Diagrams::03_Coagulation_Panel #AK_Other::Only_Step_1 #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::02_Heparin #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::03_Hypercoagulable_States #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::02_Bleeding_Time,_Prothrombin_Time,_INR,_and_Partial_Thromboplastin_Time #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::15_Antiplatelets,_Anticoagulants,_and_Thrombolytics #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::03_Antiplatelet,_Anticoagulant,_Thrombolytic_Agents #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_Hematology #AK_Step1_v12::#Pathoma::04_Hemostasis::02_Secondary_Hemostasis_&_Related_Disorders #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::07_Anticoagulant_Drugs #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::02_Secondary_Hemostasis #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::03_Heparin_(MOA,_Indications,_ADR,_CI)